[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-350761-en":3,"detail-sidebar-cat-0-en-105":51,"doc-seo-350761-105":98},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"doc_content":15,"file_id":16,"file_url":17,"file_type":18,"file_size":19,"view_count":20,"is_deleted":4,"is_public":21,"is_downloadable":21,"audit_status":21,"page_count":22,"language":23,"language_code":24,"site_id":25,"html_lang":24,"table_of_contents":26,"faqs":27,"seo_title":28,"seo_description":14,"update_tm":29,"read_time":30,"preview_page_count":31,"preview_urls":32},350761,962090883568,"anakgang17","https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd",8,"Research & Report","A nationwide survey of medical resource usage for cancer treatment using Japanese health claims data from 2011 to 2022","A nationwide retrospective cohort study analyzes healthcare resource utilization and cost drivers for cancer treatment in Japan using Japanese health claims data from April 2011 to March 2022. Patients are classified by cancer type, and monthly insurance claims and relevant medications are examined across care settings. Breast cancer is most common; lung cancer has the highest overall cost, while multiple myeloma is highest per person-month. Rapid cost growth is observed in immune checkpoint inhibitor mechanisms, with overall cancer treatment costs rising faster than national economic growth.","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nA nationwide survey of medical resource usage for cancer treatment using Japanese health claims data from 2011 to 2022  \nKeita Fukuyama1􀀍, Yukiko Mori1, Hiroaki Ueshima2, Shigemi Matsumoto3, Manabu Muto4 & Tomohiro Kuroda1  \nMultidisciplinary cancer treatments have advanced significantly, especially with molecular targeted therapies improving prognosis. Although these are expensive, their cost impact remains unverified. This study aimed to investigate the overall utilization of healthcare resources and identify the cost drivers of cancer treatment in Japan. In this retrospective cohort study, patients diagnosed with malignancies between April 2011 and March 2022 were classified by cancer type, and monthly insurance claims and applicable medications were analyzed. Breast cancer was the most common, followed by stomach and colon cancers. Cost analysis by cancer type revealed that lung cancer was the most expensive overall, whereas multiple myeloma was the most expensive per person-month. When antineoplastic drug costs were aggregated by mechanism, a rapid increase was observed in the immune checkpoint inhibitor category. Since the advent of immune checkpoint inhibitors, the number of insurance claims for antineoplastic drugs in Japan has increased. Japan’s public healthcare system has seen an increase in the cost of cancer treatment at a rate exceeding national economic growth. These findings highlight the need for policies that address the cost-effectiveness and sustainability of cancer care to ensure continued access to high-quality treatment within publicly funded systems in Japan and globally.  \nKeywords Cancer therapy, Health resource utilization, Real-world data, Antineoplastic agents, The national database of health insurance claims and specific health checkups of Japan  \nAbbreviations  \nATC Anatomical therapeutic chemical  \nCI5 Cancer incidence in five continents  \nGDP Gross domestic product  \nICD-10 International classification of diseases, Tenth revision KEGG Kyoto encyclopedia of genes and genomes MHLW Ministry of health, labor, and welfare  \nNDB National database of health insurance claims and specific health checkups of Japan PD-1 Programmed death-1  \nPDL-1 Programmed death ligand-1 VEGF Vascular endothelial growth factor  \nCancer is the leading cause of non-communicable disease deaths worldwide, with 20 million new cases and 9.7 million deaths estimated in 2022.1 Globally, approximately one in five people will develop cancer in their lifetime, and approximately one in nine men and one in 12 women will die of cancer.2 The number of patients with cancer is increasing owing to the aging global population.2 Effective cancer treatment requires a multifaceted approach that utilizes various medical resources, including diagnostic tests, surgery, chemotherapy, and radiation therapy.  \n1Division of Medical Information Technology and Administration Planning, Kyoto University Hospital, Kyoto, Japan. 2Center for Innovative Research and Education in Data Science, Institute for Liberal Arts and Sciences, Kyoto University, Kyoto, Japan. 3Department of Real World Data Research and Development, Graduate School of Medicine, Kyoto University, Kyoto, Japan. 4Department of Medical Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. 􀀍 [email: fkeita@kuhp.kyoto-u.ac.jp](email: fkeita@kuhp.kyoto-u.ac.jp)  \nRecently, developments in molecular targeted therapy and immunotherapy have led to favorable treatment outcomes for several cancers, such as tyrosine kinase inhibitors or immune checkpoint inhibitors for nonsmall cell lung cancer,3 hepatocellular carcinoma,4 and renal cell carcinoma.5 However, the drugs used in these treatments are generally expensive, and there are concerns that cancer treatment will place a strain on health insurance finances.6 In a cross-cancer study, Chen et al.7 reported that in several countries, the highest estimate","cbCaipdYdIFNtcr6","https://ap.wps.com/l/cbCaipdYdIFNtcr6","pdf",1965950,6,1,10,"English","en",105,"# Background\n## Cancer burden and treatment needs\n## Rationale for studying costs in Japan\n# Data and Methods\n## Retrospective cohort design\n## Classification and analysis of claims\n# Results\n## Cancer type distribution\n## Cost findings by cancer type\n## Trends in antineoplastic drug mechanisms\n# Discussion\n## Growth of immune checkpoint inhibitor use\n## Implications for policy and sustainability\n# Conclusions\n## Need for cost-effectiveness and access-focused policies","[{\"question\":\"What is the main purpose of this nationwide survey?\",\"answer\":\"To quantify overall utilization of healthcare resources and identify cost drivers of cancer treatment in Japan using health claims data.\"},{\"question\":\"How were patients and claims analyzed in the study?\",\"answer\":\"Patients diagnosed between April 2011 and March 2022 were grouped by cancer type, and monthly insurance claims and applicable medications were analyzed.\"},{\"question\":\"Which cancer types had the highest costs overall and per person-month?\",\"answer\":\"Lung cancer had the highest overall cost, while multiple myeloma had the highest cost per person-month.\"}]","A nationwide survey of medical resource usage for cancer treatment using Japanese health claims data from 2011 to 2022 | PDF",1790090948,25,4,[33,37,42,47],{"page_no":21,"url":34,"width":35,"height":36},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/179856cbfc835274b88c8d6df4e6071d.webp",983,1291,{"page_no":38,"url":39,"width":40,"height":41},2,"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c3dfbbb0649fd8cc5861fcadb77ccbf1.webp",982,1290,{"page_no":43,"url":44,"width":45,"height":46},3,"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/73a34a36918d753dd2edb7a0cc01e038.webp",981,1289,{"page_no":31,"url":48,"width":49,"height":50},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e9d79aa290a8514d44acb4b798a7a6a1.webp",980,1287,{"code":4,"msg":5,"data":52},[53,58,62,66,71,75,80,83,88,91,94],{"id":21,"doc_module":4,"doc_module_name":54,"category_name":55,"show_sort_weight":56,"slug":57},"Document","Story & Novel",90,"story-novel",{"id":38,"doc_module":4,"doc_module_name":54,"category_name":59,"show_sort_weight":60,"slug":61},"Literature",80,"literature",{"id":31,"doc_module":4,"doc_module_name":54,"category_name":63,"show_sort_weight":64,"slug":65},"Exam",70,"exam",{"id":67,"doc_module":4,"doc_module_name":54,"category_name":68,"show_sort_weight":69,"slug":70},5,"Comic",60,"comic",{"id":20,"doc_module":4,"doc_module_name":54,"category_name":72,"show_sort_weight":73,"slug":74},"Technology",50,"technology",{"id":76,"doc_module":4,"doc_module_name":54,"category_name":77,"show_sort_weight":78,"slug":79},7,"Healthcare",40,"healthcare",{"id":11,"doc_module":4,"doc_module_name":54,"category_name":12,"show_sort_weight":81,"slug":82},30,"research-report",{"id":84,"doc_module":4,"doc_module_name":54,"category_name":85,"show_sort_weight":86,"slug":87},9,"Religion & Spirituality",20,"religion-spirituality",{"id":86,"doc_module":4,"doc_module_name":54,"category_name":89,"show_sort_weight":86,"slug":90},"World Cup","world-cup",{"id":22,"doc_module":4,"doc_module_name":54,"category_name":92,"show_sort_weight":22,"slug":93},"Lifestyle","lifestyle",{"id":95,"doc_module":4,"doc_module_name":54,"category_name":96,"show_sort_weight":67,"slug":97},19,"General","general",{"code":4,"msg":99,"data":100},"ok",{"site_id":25,"language":24,"slug":101,"title":13,"keywords":102,"description":14,"schema_data":103,"social_meta":156,"head_meta":158,"extra_data":160,"updated_unix":161},"a-nationwide-survey-of-medical-resource-usage-for-cancer-treatment-using-japanese-health-claims-data-from-2011-to-2022","",{"@graph":104,"@context":155},[105,118,138],{"@type":106,"itemListElement":107},"BreadcrumbList",[108,112,114,116],{"item":109,"name":110,"@type":111,"position":21},"https://docshare.wps.com","Home","ListItem",{"item":113,"name":54,"@type":111,"position":38},"https://docshare.wps.com/document/",{"item":115,"name":12,"@type":111,"position":43},"https://docshare.wps.com/document/research-report/",{"item":117,"name":13,"@type":111,"position":31},"https://docshare.wps.com/document/a-nationwide-survey-of-medical-resource-usage-for-cancer-treatment-using-japanese-health-claims-data-from-2011-to-2022/350761/",{"url":117,"name":13,"@type":119,"image":120,"author":125,"headline":13,"publisher":127,"fileFormat":130,"inLanguage":24,"description":14,"dateModified":131,"datePublished":132,"encodingFormat":130,"isAccessibleForFree":133,"interactionStatistic":134},"DigitalDocument",{"url":121,"@type":122,"width":123,"height":124},"https://docshare.wps.com/thumbnails/a-nationwide-survey-of-medical-resource-usage-for-cancer-treatment-using-japanese-health-claims-data-from-2011-to-2022/350761.png","ImageObject",300,407,{"name":9,"@type":126},"Person",{"url":109,"name":128,"@type":129},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":135,"interactionType":136,"userInteractionCount":20},"InteractionCounter",{"@type":137},"ViewAction",{"@type":139,"mainEntity":140},"FAQPage",[141,147,151],{"name":142,"@type":143,"acceptedAnswer":144},"What is the main purpose of this nationwide survey?","Question",{"text":145,"@type":146},"To quantify overall utilization of healthcare resources and identify cost drivers of cancer treatment in Japan using health claims data.","Answer",{"name":148,"@type":143,"acceptedAnswer":149},"How were patients and claims analyzed in the study?",{"text":150,"@type":146},"Patients diagnosed between April 2011 and March 2022 were grouped by cancer type, and monthly insurance claims and applicable medications were analyzed.",{"name":152,"@type":143,"acceptedAnswer":153},"Which cancer types had the highest costs overall and per person-month?",{"text":154,"@type":146},"Lung cancer had the highest overall cost, while multiple myeloma had the highest cost per person-month.","https://schema.org",{"og:url":117,"og:type":157,"og:title":13,"og:site_name":128,"og:description":14},"article",{"robots":159,"canonical":117},"index,follow",{"doc_id":7,"site_id":25},1790211494]